Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Series B to Accelerate Clinical Drug Development & CDMO Industrial Base

　　Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed a Series B financing round exceeding CNY 200 million,which were led by Changjiang Venture Capital ,with participation from Hongcheng Capital and Hangzhou Huadian Investment, and continued support from Yangtze River Industry Group and SDIC Capital. The raised funds will be used to accelerate the clinical development of the company's core innovative drug products and the construction of its CDMO industrial base.

　　Following the successful completion of its Series A financing in April this year, Jiangsu Vcare has once again secured Series B funding amid a complex and volatile market environment, fully demonstrating its strong growth potential and robust core competitiveness. In recent years, Jiangsu Vcare has maintained steady development, continuously expanding its scale, with its workforce now approaching 600 employees. The company has also strengthened industry-academia-research collaboration, signing strategic cooperation agreements with multiple universities.

　　The parent company, Jiangsu Vcare, is deeply focused on the development of innovative drugs and cutting-edge therapies, with over ten innovative drug pipelines in its portfolio. Several core clinical-stage products have reached critical milestones: Vicagrel, a Class I novel anti-thrombotic drug, recently completed patient enrollment in its global multi-center pivotal clinical trial (covering China and the U.S.), positioning it to fully address the clinical challenges arising from clopidogrel metabolism.VC004, an anti-tumor new drug, is a second-generation NTRK inhibitor with anti-resistance properties. It has demonstrated significant efficacy and favorable safety in its Ib trial involving NTRK fusion-positive patients (including those resistant to first-generation inhibitors). Preparations for Phase II trials are now underway. VC005, a second-generation selective JAK1 inhibitor, has successively received clinical approvals for expanded indications, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and atopic dermatitis, and is currently in the Phase II initiation stage. Additionally, the company is advancing multiple preclinical pipelines, covering targets such as SHP2, ER-PROTAC, IL-17A, and more.

　　The wholly-owned subsidiary, Nanjing Vcare Pharmatech Co., Ltd. (Nanjing Vcare), has further deepened its one-stop CRO/CDMO service platform, achieving continuous upgrades and optimizations. It has completed the construction of its Phase II CDMO R&D Technology Center, been recognized as a "Technology-based SME", and ranked among the "Top 10 CRO Enterprises in China". Nanjing Vcare has also successfully acquired Hubei Tianshu Pharmaceutical Co., Ltd. , a CDMO production base currently under rapid construction, with operations expected to commence in Q1 next year. This will establish an advanced production service platform, effectively integrating R&D and manufacturing synergies to accelerate business growth.

　　"Unity brings strength, collaboration creates momentum; long-term vision ensures endurance, and lofty goals lead to far-reaching success." Since its founding in 2010, Jiangsu Vcare has adhered to a dual-track industrial strategy, combining independent innovative drug R&D with full-chain pharmaceutical services. With the further support of its Series B investors, Jiangsu Vcare is poised to navigate the tides of change and embark on a journey toward broader horizons.

　　Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We sincerely thank our investors for their recognition of Jiangsu Vcare's innovation capabilities, execution strength, core business progress, and growth potential, as well as their continued trust in us despite the complex pandemic and volatile market conditions. This fully affirms the reliable capabilities and long-term value that Jiangsu Vcare, as an emerging pharmaceutical company with rapid development momentum, has demonstrated in the industry. We will remain true to our original aspirations, driven by innovation, and continue to strengthen our core competencies. By focusing on unmet clinical needs and deeply understanding client project requirements, we aim to contribute to the enhancement of China's pharmaceutical industry chain and accelerate internationalization, while creating sustainable long-term value for our shareholders."